Will supply chain demands freeze Pfizer and BioNTech out of a big chunk of the Covid-19 market?
Since the start of the pandemic, far more attention has been paid to developing a vaccine than to the sticky process of actually getting that vaccine, once developed, to people.
As the first vaccines near possible approval, though, that question is gaining urgency, and it’s posing a particular problem for the new technology that has allowed some of these candidates to move so quickly: mRNA. To remain stable, mRNA vaccines have to be stored at incredibly low temperatures — as low as -80 degrees Celsius (-112 Fahrenheit). Distributing them, experts have warned, pose a major logistical challenge for the US and an even greater challenge to the world.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.